Abstract
In simplest terms, consciousness is defined as the state of awareness of the self and environment. 1 Conscious behavior requires adequate arousal (i.e., wakefulness) and awareness of content (i.e., sensory, cognitive, and affective experience). Severe acquired brain injury (ABI) is a catastrophic event that disrupts the brain's arousal and awareness systems, which are mediated by the brainstem and cortex, respectively. The most severe injuries result in prolonged (i.e., lasting at least 28 days) disorders of consciousness (DoC), including the vegetative state (VS) 2 and the minimally conscious state (MCS). 3 VS is also referred to as postcoma unawareness 4 or unresponsive wakefulness syndrome (UWS). 5 In this guideline, the term UWS is used synonymously with VS. While this term has no special merit or mandate for use in clinical practice, it is included here because of its wide acceptance in Europe. Table e-1 (links.lww.com/WNL/A611) provides the definitions for VS and MCS and other key terms pertinent to DoC.
The cost of lifetime care for persons with prolonged DoC can exceed $1,000,000. 6 Despite the enormity of the problem, few practice guidelines are available. In 1995, the American Academy of Neurology (AAN) published diagnostic and prognostic guidelines for persistent VS (PVS) 7 following an evidence-based review completed by the Multi-Society Task Force (MSTF) on PVS. 2 In 2002, the Aspen Neurobehavioral Workgroup defined MCS and published consensus-based diagnostic criteria. 3 Both reports focused on diagnosis, as data addressing prognosis and treatment were sparse.
Based on available epidemiologic data, 8 the annual US incidence of VS is approximately 4,200 persons. The incidence of MCS is unknown largely because it has no diagnostic code in the International Classification of Diseases classification system. Prevalence figures for VS/UWS and MCS in the United States are hampered by economic factors that lead patients with DoC to be transferred from the acute care setting to long-term care facilities, where they are often lost to follow-up. Prevalence estimates range from 5,000 to 42,000 persons for VS/UWS [9] [10] [11] and 112,000 to 280,000 persons for MCS using a proxy definition. 12 Published estimates of misdiagnosis among patients with DoC consistently approximate 40% in both US and European studies. [13] [14] [15] In the most recent study, 13 41% of patients with a clinical diagnosis of VS/UWS based on team consensus (n = 44) were actually in MCS when reevaluated by the investigators using a standardized neurobehavioral scale. In addition, 89% of those with an uncertain diagnosis (n = 18) were found to have clear signs of consciousness on standardized examination. Findings from the other 2 studies 14, 15 were in the same direction. Underlying visual or motor impairments interfering with detection of command-following and failure to detect visual pursuit are frequent causes of failure to recognize MCS. The rate of diagnostic error underscores the need for more refined evaluation methods. This concern extends to the criteria for emergence from MCS (eMCS), as some investigators suggest that the existing criteria lead to overdiagnosis of this condition. 16 Now is an opportune time to reevaluate current diagnostic approaches. Apart from the extensive list of specialized neurobehavioral assessment instruments that have been released since the MSTF and Aspen Neurobehavioral Workgroup reports were published, 2,17 a growing body of research suggests that functional neuroimaging techniques, such as fMRI and PET, may be able to detect suggestions of conscious awareness in the absence of bedside evidence. [18] [19] [20] [21] Natural history studies of patients with prolonged DoC now include outcomes extending beyond 1 year. This provides an opportunity to reassess the 1994 MSTF introduction of the term permanent VS (table e-1, links.lww.com/WNL/A611), which is questioned based on the methodology used to calculate the incidence of recovery of consciousness beyond 12 months 22 and the total number of individuals available for follow-up after 12 months (i.e., 30). 23 Increasingly, publications are also available for DoC prognosis and treatment, with recent multicenter randomized clinical trials available to determine the effectiveness of specific interventions for patients with prolonged DoC.
The purpose of this systematic review and accompanying guideline is to update the 1995 AAN PVS guideline 7 and the 2002 MCS case definition. 3 This article summarizes the systematic review findings and conclusions. The guideline recommendations are published separately. 24 Full text of the systematic review and guideline, including appendices e-1 to e-9, is available as a data supplement at links.lww.com/WNL/ A610. Tables e-1 to e-3 and references e1 through e42, Glossary AAN = American Academy of Neurology; CI = confidence interval; DoC = disorders of consciousness; eMCS = emergence from minimally conscious state; LEP = laser-evoked potential; LR = likelihood ratio; MCS = minimally conscious state; MSTF = Multi-Society Task Force; OR = odds ratio; PVS = persistent vegetative state; UWS = unresponsive wakefulness syndrome; VS = vegetative state.
overarching questions concerning patients with traumatic and nontraumatic DoC: (1) What procedures accurately diagnose prolonged DoC, where prolonged DoC is defined as lasting at least 28 days? (2) What is the natural history of prolonged DoC? (3) What factors or procedures help to predict outcome in prolonged DoC? (4) What treatments are effective for prolonged DoC?
Description of the analytic process
This systematic review and accompanying practice guideline were developed in accordance with the process described in the 2011 AAN Clinical Practice Guideline Process Manual, as amended. 25 The full guideline provides a description of the exact methodology followed, including the processes of convening the author panel, performing the literature search, and reviewing the evidence and application of a modified Grading of Recommendations Assessment, Development and Evaluation (GRADE) process. 26 Recommendations were based not only on the evidence in the systematic review, but also on strong related evidence, established principles of care, and inferences. The level of obligation for each recommendation was based on the strength of these premises and the riskbenefit ratio of following the recommendation, with adjustments based on importance of outcomes, variation in patient preferences, feasibility/availability, and patient costs. Consensus was determined by a modified Delphi voting process in accordance with prespecified rules. 25 Inclusion criteria relevant for all questions were (1) population had a DoC for at least 28 days and (2) the study enrolled at least 20 patients with a prolonged DoC. The 28-day cutoff was employed to ensure that patients in coma were excluded, as good outcome is not uncommon following transient coma, unlike prolonged VS/UWS and MCS. Articles were accepted only if the entire participant population met the criterion of having a DoC for at least 28 days or if the article presented data for this cohort separately. This approach was determined a priori and resulted in the exclusion of some high-quality studies. This is discussed further in the Putting the Evidence in a Clinical Context section.
Analysis of evidence

Diagnostic assessment
For the diagnostic question, the guideline panel considered patients with traumatic or nontraumatic VS/UWS or MCS at least 28 days postinjury and asked if any diagnostic assessment procedures accurately detect behavioral signs of consciousness or differentiate specific DoC compared with standardized behavioral assessment. Readers are referred to a previously published systematic review completed by the American Congress of Rehabilitation Medicine Disorders of Consciousness Task Force that provides evidence-based recommendations for clinical use of standardized behavioral assessment methods (work not repeated in this project). 17 Study results were assessed using likelihood ratios (LRs), which are described in the full-length guideline.
Eight diagnostic articles were Class I for at least some procedures, 27 27 normal or mildly abnormal background on EEG, 29, 31 the combination of a low-voltage background EEG pattern and lack of EEG reactivity, 31 specific entropy measures, 38 the absence of Aδ-fiber laser-evoked potential (LEP) N2P2 or C-fiber LEP N2P2 components in response to LEPs, e2 evidence of exogenous or endogenous attention as assessed by the P3a and P3b components of P300 in response to word stimuli, 35 a nasal cannula "sniff controller," 28 command-following on an fMRI motor imagery task, 29 use of an fMRI incorrect-minus-correct activation protocol, 36 resting-state MRI, 37 structural MRI, 37 or fluorodeoxyglucose-PET, 37 often due to limited precision. It is possible that fMRI using a word-counting task is not helpful in distinguishing between MCS and VS (low confidence in the evidence, 1 Class I study, 33 with the LR+ suggesting no change in the probability of MCS with testing and confidence intervals (CIs) suggesting values of slight importance at most; LR+ 1.00, 95% CI 0.33-2.99). Results for this study were affected by the fact that 3 of 8 patients diagnosed with VS/UWS based on the absence of command following on the CRS-R had the suggestion of fMRI activation with the task (37.5%, 95% CI 13.7%-69.4%), the implications of which are uncertain.
Natural history
Eighteen articles e3-e20 (links.lww.com/WNL/A612) met inclusion criteria for the natural history question. Results were analyzed separately by DoC diagnosis and etiology; studies only reporting mixed etiology populations are described in the full-length guideline. No studies examined the natural history of patients in traumatic or nontraumatic MCS in a manner allowing outcome to be determined at specific times postinjury. It is possible that 60% of patients with nontraumatic VS/UWS (95% CI 45%-74%) will survive to 6-8 months (low confidence in the evidence, 2 Class III studies).
e3,e13
Prognostic assessment For the prognostic question, the guideline panel first evaluated the prognostic relevance of DoC diagnosis (VS/UWS vs MCS) and of mechanism of injury. Then, the panel separately considered prognostic factors in patients with traumatic or nontraumatic VS/UWS or MCS at least 28 days postinjury because this information has the most clinical relevance. Prognostic factors for which there was insufficient evidence are described only in the full-length guideline.
Prognostic factors in adult populations
Four Class II studies e6,e8,e21,e22 (links.lww.com/WNL/A612) examined the prognostic value of diagnoses of MCS vs VS/ UWS. In prolonged DoC of traumatic origin, a diagnosis of MCS, as opposed to VS/UWS, is probably associated with increased odds of better than severe disability at 12 months (moderate confidence in the evidence, 1 Class II study e22 with increased confidence in the evidence due to magnitude of effect). In patients with prolonged DoC of mixed etiology, a diagnosis of MCS is possibly associated with increased odds of improvement vs VS/UWS (odds ratio [OR] 4.72, 95% CI 1.13-19.71, I 2 = 66%) (low confidence in the evidence, metaanalysis of 3 Class II studies e8,e21,e22 with insufficient precision to drive recommendations individually). In patients with a prolonged DoC of mixed etiology already present for over a year, a diagnosis of VS/UWS is possibly associated with increased odds of deterioration in functional status over subsequent years (OR 3.37, 95% CI 1.28-8.87) (low confidence in the evidence, 1 Class II study). One Class I and 4 Class II studies examined the prognostic value of traumatic vs nontraumatic injury in patients with prolonged DoC e6,e8,e21-e23 (links.lww.com/WNL/A612). In patients with prolonged MCS, a traumatic etiology is probably associated with increased odds of better than severe disability at 12 months (OR 11.0, 95% CI 1.9-63.2, moderate confidence in the evidence, 1 Class II study e24 with increased confidence in the evidence due to magnitude of effect). In mixed populations including patients with MCS and VS/UWS, traumatic DoC is probably associated with increased odds of improvement (defined generally due to differences in study design; OR 9.41, 95% CI 2.03-43.53; moderate confidence in the evidence, 3 Class III studies, e8,e21,e24 2 of which had sufficient precision on their own e21,e24 combined in a metaanalysis with overall increased confidence in the evidence due to magnitude of effect). 34 with decreased confidence in the evidence due to precision).
EEG
It is possible that EEG reactivity to at least one type of sensory stimulus distinguishes MCS from VS to a mildly important degree (low confidence in the evidence; 1 Class I study 31 with decreased confidence in the evidence due to precision; LR+ 2.00, 95% CI 1.43-2.80).
Evoked potentials
It is possible that the presence of Aδ-LEP N2P2 and C-LEP N2P2 components in response to LEPs distinguishes MCS from VS to a mildly important degree (low confidence in the evidence; 1 Class I study 32 with decreased confidence in the evidence due to precision; LR+ 2.30, 95% CI 1.43-3.67).
PCI score
It is possible that a PCI >0.31 distinguishes MCS from VS/UWS to a mildly important degree (low confidence in the evidence, 1 Class I study 30 with decreased confidence in the evidence due to precision; LR+ 3.375, 95% CI 1.87-6.09).
Abbreviations: CI = confidence interval; LEP = laser-evoked potential; LR+ = positive likelihood ratio; MCS = minimally conscious state; PCI = Perturbational Complexity Index; VS/UWS = vegetative state/unresponsive wakefulness syndrome. Abbreviations: CRS-R = Coma Recovery Scale-Revised; DRS = Disability Rating Scale; MCS = minimally conscious state; MLAEP = middle latency auditory evoked potential; MMN = mismatch negativity; SEP = somatosensory evoked potential; VS/UWS = vegetative state/unresponsive wakefulness syndrome. a Some of these study cohorts are just patients with VS/UWS or MCS and some are mixed; see full guideline for details.
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Prognostic factors in pediatric populations
In pediatric patients, traumatic (vs anoxic) etiology of VS/UWS present for at least 30 days is possibly associated with increased odds of recovery at 3-12 months (low confidence in the evidence, 1 Class II study e36 [links.lww.com/WNL/A612]). A traumatic etiology, as compared to an anoxic injury, is probably also associated with a better quality outcome (moderate confidence in the evidence, 1 Class II study e36 with increased confidence due to magnitude of effect). In pediatric patients with a DoC for at least 90 days, a traumatic etiology, as compared with an anoxic injury, is possibly associated with better cognitive and motor outcomes and increased odds of taking feedings orally (low confidence in the evidence, 1 Class II study e37 ). Other prognostic features are described in table 3.
Therapeutic intervention
Two Class I therapeutic studies e38,e39 (links.lww.com/WNL/ A612) and 1 Class III therapeutic study e40 were identified. Amantadine probably hastens functional recovery in patients with MCS or VS/UWS secondary to severe traumatic brain injury over 4 weeks of treatment (moderate confidence in the evidence, 1 Class I study e38 ) and appears safe in this population. There is insufficient evidence to support or refute continuation of benefit once amantadine is discontinued (very low confidence in the evidence, 1 Class I study e38 with insufficient precision). In patients with VS/UWS of mixed etiologies, conventional tilt table treatment is probably superior to tilt table treatment incorporating an integrated stepping device for improving level of arousal (moderate confidence in the evidence based on 1 Class I study e39 ), but the benefit of tilt table treatment vs placebo/nontreatment is not established (no identified studies).
Putting the evidence in a clinical context
The results of this systematic review highlight important gaps in knowledge related to diagnosis, natural history, prognosis, and treatment for patients with prolonged DoC. Some consistent weaknesses in study methodology were observed across studies, constraining the strength of the evidence. Small sample size was the most prevalent weakness due to limited study precision and generalizability.
In addition, the number of available studies was constrained by the a priori inclusion criteria of the guideline. The decision to include only studies investigating participants who were at least 28 days postinjury disqualified many studies conducted in the acute care setting, as well as those that either combined, or did not specify, the number of participants above and below this threshold. Some well-designed studies in which the majority of the participants met the 28-day inclusion criterion are considered in the rationale for recommendations as strong related evidence but could not contribute to the systematic review. Below, the guideline panel describes trends in study design within each of the 4 areas that compromised the strength of the evidence.
Diagnostic assessment
The most important challenge to validating more precise diagnostic approaches is the absence of an established reference (gold) standard with adequate sensitivity and specificity. The most commonly used reference standard (team consensusbased diagnosis) is associated with a 30%-40% error rate. [13] [14] [15] Thus, it is difficult to discern whether disagreement between the reference standard and a novel assessment measure reflects a false-positive or false-negative error on the part of the novel measure, or evidence that the novel measure has outperformed the reference standard. A second recurrent weakness in diagnostic studies is the infrequent use of masking procedures. Masking is essential to protect against examiner bias, which is particularly important when the assessment approach relies on nonobjective measures.
Natural history
Investigation of the natural history of recovery from severe brain injury requires a systematic approach to tracking selected milestones (e.g., mortality, recovery of consciousness, improvement in degree of disability). Many of the studies failed to report or control for the length of time from injury and instead anchored follow-up to date of admission to the inpatient rehabilitation setting. A study reporting that emergence from MCS occurs an average of 45 days after admission to the rehabilitation hospital is of limited clinical utility if the time to admission ranged from 4 to 52 weeks postinjury. Studies often failed to stratify or subanalyze participants by diagnostic subtype (VS/UWS vs MCS) and etiology (traumatic/nontraumatic), obscuring the trajectory of recovery. The fact that most natural history studies enroll participants at specialty rehabilitation centers is a further limitation, as these results may not generalize to individuals without access to specialty rehabilitation services.
Finally, relatively few natural history and prognostic studies reported long-term functional outcomes. In many studies, outcome assessment focused exclusively on recovery of consciousness or eMCS or both, without attention to the corresponding level of disability. Importantly, studies that tracked functional outcome beyond 1 year suggest up to 1 in 5 patients with prolonged DoC-especially those who transition to MCS before 6 months-eventually regain independence in the home environment e41,e42 (links.lww.com/WNL/A612). DoC outcome research will be of greater relevance to clinicians, patients, and families by ensuring that results address the degree of functional improvement attained.
Prognostic assessment
The majority of studies investigating the predictive utility of patient and injury characteristics were conducted retrospectively, which subjected these studies to some of the same limitations noted in the natural history studies. Because inclusion criteria did not address specific clinical features known to be linked to outcome (e.g., diagnostic subtype, injury etiology, and length of time postinjury), within-sample variability tended to be high along these dimensions, contributing to wide CIs and imprecise outcome projection. In addition, risk factors and outcomes were often not assessed independently, allowing the possibility that factors believed to affect prognosis may have inappropriately influenced clinical decisions and contributed to unfavorable outcomes (including decisions to discontinue life-sustaining care).
Therapeutic interventions
Most treatment studies were excluded because the intervention was studied during the acute phase of recovery, there was no control group, or the study was not methodologically sound. DoC treatment studies face challenges not encountered in clinical trials conducted in other populations. First, the number of patients with prolonged DoC admitted to inpatient rehabilitation settings has progressively declined over the last 15 years. This trend is influenced by a number of factors, including a tendency by insurers to preferentially authorize rehabilitative care in lower-cost settings such as skilled nursing facilities. Consequently, it is difficult to enroll a large enough sample to support a sufficiently powered therapeutic study. Constraints on sample size also limit stratification of participants to account for differences in treatment effect related to mediating factors such as cause of injury, chronicity, and number of comorbidities.
A second challenge arises in the context of the rehabilitation setting. The typical length of inpatient rehabilitation in many academic medical centers has fallen below 20 days. Under these circumstances, family members are often reticent to enroll patients with prolonged DoC in a placebo-controlled trial in view of the 50% likelihood of assignment to the placebo arm, preventing any possibility of active treatment during rehabilitation apart from routine physical, occupational, and speech therapies.
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